| Literature DB >> 32309286 |
Md Nur Hossain1, Sadia Afrin1, Sanjida Humayun1, Monzur Morshed Ahmed1, Barun Kanti Saha1.
Abstract
The nonpathogenic yeast Saccharomyces boulardii (Sb) has beneficial effects on the human intestine, and thus has been prescribed as probiotics for the treatment of diarrhea and gastrointestinal diseases. This is the only commercialized yeast with the purpose of being used as human medicine. Currently, little is known about their multiple mechanisms of actions. The S. boulardii yeast strain is isolated and identified by using the BIOLOGTM microarray identification system and morphologically. To understand its functional roles, the present study investigates the ability of this yeast to tolerate different concentrations of bile salt up to 2.5%, cell hydrophobicity, antioxidants, autoaggregation activity, and simulated gastrointestinal digestion. The effect of temperatures (up to 50°C), pH (up to 8.0), and salinity (at best 7%) was also monitored on the growth and survival of the yeast cell. The physicochemical analyses revealed that S. boulardii could survive in stomach conditions at pH 2.5, temperature 37°C, and 2% bile salt. Antibiotic susceptibility of S. boulardii was carried out using commercial antibiotic discs. The antimicrobial activity of the isolated S. boulardii against bacterial pathogens related to diarrhea diseases was in-vitro determined by the Well Diffusion method. The biosafety assay findings also claimed S. boulardii could be a potential probiotic. The experimental findings suggest that the isolated S. boulardii possesses excellent probiotic capacities as a biotherapeutic agent for antidiarrheal and gastrointestinal disorders.Entities:
Keywords: BIOLOGTM identification; Saccharomyces boulardii; antimicrobial activity; gastrointestinal disorders; probiotic
Year: 2020 PMID: 32309286 PMCID: PMC7145964 DOI: 10.3389/fnut.2020.00027
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Figure 1Microscopic observation of S. boulardii cells. (A) Oval and/or spherical shapes under low power objective. (B) Budding of S. boulardii under high power objective.
Biochemical characteristics of the S. boulardii strain.
| Nitrogen utilization | Nitrate | – |
| Peptone | + | |
| Ammonium sulfate | + | |
| Carbon utilization | Glucose | + |
| Fructose | + | |
| Sucrose | + | |
| Lactose | – | |
| Starch | + | |
| Acid production | + | |
| Ester production | + | |
| Urea hydrolysis | – | |
| Gelatin Liquefaction Test | – | |
| H2S Test | Brownish, Black | |
Microorganism identification with BIOLOGTM system.
| Yeast strain | 0.863 | 0.581 | 5.000 |
Figure 2Effect of temperature, bile, pH and NaCl on the growth of S. boulardii. (A) Temperature stability. (B) Bile salt tolerance. (C) pH resistance capacity. (D) NaCl Tolerance.
Figure 3In-vitro gastrointestinal digestion effect on the growth of S. boulardii.
Antibiotic susceptibility profile of S. boulardii isolate.
| Cefotaxime | 30 μg | 23.0 | S |
| Ciprofloxacin | 5 μg | 21.0 | S |
| Erythromycin | 15 μg | 24.0 | S |
| Imipenem | 10 μg | 15.0 | R |
| Kanamycin | 30 μg | 19.0 | S |
| Chloramphenicol | 30 μg | 14.0 | MS |
| Rifampicin | 30 μg | 19.0 | MS |
| Vancomycin | 30 μg | 13.0 | MS |
| Ampicillin | 10 μg | 8.0 | R |
| Amikacin | 30 μg | 12.0 | R |
| Gentamicin | 10 μg | 16.0 | S |
| Metronidazole | 5 μg | 24.0 | S |
MS, moderately sensitive; R, resistant; S, sensitive.
Antimicrobial activity of S. boulardii against test pathogens, inhibition zone measured in mm (mean ± SD).
| 22.0 ± 0.30 | Bs | |
| 30.0 ± 0.21 | Bc | |
| 23.0 ± 0.26 | Bs | |
| 21.0 ± 0.24 | Bs | |
| 26.0 ± 0.28 | Bc | |
| 22.5 ± 0.31 | Bs | |
| 24.5 ± 0.28 | Bs | |
| 20.5 ± 0.29 | Bs | |
| 22.0 ± 0.32 | Bs | |
| 24.0 ± 0.27 | Bs | |
| 17.6 ± 0.13 | Bs | |
| 23.5 ± 0.27 | Bs | |
| 18.3 ± 0.19 | Bs | |
Bc, Bactericidal, Bs, Bacteriostatic.
S. boulardii and Enterobacteria counts along with feces conditions in tested the mice feces.
| C1 | 0 | 0 | 0 | 0 | |
| Enterobacteria | 4.65 ± 0.10 | 5.46 ± 0.29 | 6.73 ± 0.19 | 7.10 ± 0.16 | |
| Feces conditions | Normal | Normal | Normal | Normal | |
| C2 | 0 | 0 | 0 | 0 | |
| Enterobacteria | 4.25 ± 0.38 | 4.72 ± 0.07 | 5.95 ± 0.21 | 6.81 ± 0.30 | |
| Feces conditions | Normal | Normal | Normal | Normal | |
| T1 | 6.92 ± 0.19 | 7.64 ± 0.13 | 8.23 ± 0.17 | 9.87 ± 0.39 | |
| Enterobacteria | 4.64 ± 0.11 | 5.84 ± 0.22 | 5.20 ± 0.06 | 3.92 ± 0.14 | |
| Feces conditions | Watery | Watery | Looser | Normal | |
| T2 | 7.10 ± 0.26 | 7.52 ± 0.21 | 8.20 ± 0.34 | 9.30 ± 0.21 | |
| Enterobacteria | 4.70 ± 0.06 | 5.12 ± 0.23 | 4.84 ± 0.14 | 3.70 ± 0.09 | |
| Feces conditions | Watery | Normal | Normal | Normal | |
Figure 4Body weight comparison of tested mice.